Age at cytomegalovirus, Epstein Barr virus and varicella zoster virus infection and risk of atopy: The Born in Bradford cohort, UK

Lucy Pembrey1 | Dagmar Waiblinger2 | Paul Griffiths3 | John Wright2

Abstract

Background: The prevalence of allergic diseases has increased in recent decades, but the causes remain unclear. Changes in the epidemiology of childhood infections could have contributed, but the current evidence is inconclusive. This study aims to investigate whether age at cytomegalovirus (CMV), Epstein-Barr virus (EBV) or varicella zoster virus (VZV) infection is associated with the development of atopy.

Methods: A total of 2559 children were enrolled in the Born in Bradford Allergy and Infection Study. Serum samples collected at 12 and 24 months were tested for CMV-IgG, EBV-IgG and VZV-IgG for 1000 children to establish age at infection. Skin prick testing (SPT) was conducted at age 4 years.

Results: Serology and SPT results were available for 740 children. Of these, 135 (18%) were atopic. In girls, there was a strong association of CMV infection in the second year with increased odds of atopy (adjusted OR 4.38, 95% CI 1.87-10.29) but this was not observed in boys. Age at EBV or VZV infection was not associated with risk of atopy in unadjusted analysis, but there was effect modification by sex; girls infected with VZV in the second year of life had increased odds of atopy (adjusted OR 2.85, 95% CI 1.29-6.30).

Conclusions: Our results highlight potential sex-specific effects of age at CMV infection and age at VZV infection on risk of atopy, which provide insight into the mechanisms involved in the development of atopy.

Keywords
age at infection, atopy, birth cohort, cytomegalovirus, Epstein-Barr virus

1 Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK
2 Bradford Institute for Health Research, Bradford, UK
3 Centre for Virology, University College London Medical School, London, UK

Correspondence
Lucy Pembrey, Department of Medical Statistics, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.
Email: Lucy.Pembrey@lshtm.ac.uk

Funding information
This work was supported by the Wellcome Trust (grant numbers: 083521/Z/07/Z, 083521/Z/07/A) and the European Commission; MeDALL is a collaborative project funded by the Health Cooperation Work Programme of the 7th Framework programme (grant agreement No. 261357). Funding was also provided by the National Institute for Health Research (NIHR) under its Collaboration for Applied Health Research and Care (CLAHRC) for Yorkshire and Humber. Lucy Pembrey is currently funded by the AsthmaPhenotypes Study Grant; European Research Council under the European Union's Seventh Framework Programme (FP7/2007-2013)/ERC grant agreement no. 668954 and a National Institute for Health Research, Health Technology Assessment grant (no. 16/150/06).

Edited by: Jon Genuneit

1 INTRODUCTION

The hygiene hypothesis proposes that the dramatic rise in prevalence of eczema, hay fever and allergic asthma in recent decades is due to a reduction in childhood infections.1,2 However, many studies have investigated proxy measures for childhood infections such as birth order and childcare3,4 or have focussed on symptomatic, clinically diagnosed infections.5-7
Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and varicella zoster virus (VZV) are persistent herpesviruses commonly acquired in childhood. CMV and EBV are usually asymptomatic, and VZV causes chickenpox. There is good evidence that CMV and EBV affect the developing immune system.\(^8,9\) CMV impacts on T-cell\(^10\) and NK cell\(^11,12\) differentiation, and CMV seropositivity is associated with inflammation, atherosclerosis and immunosenescence.\(^13,14\) EBV is associated with immune disorders such as multiple sclerosis and lymphoma.\(^15,16\) The features of CMV and EBV in particular indicate that changes in the epidemiology of these infections could have contributed to the increases in eczema, hay fever and allergic asthma.

In a Swedish study, no association was found between CMV or EBV seropositivity at age 4 and asthma, hay fever or eczema, although CMV-positive/EBV-negative children were more likely to have specific IgE to common allergens than children seronegative for both infections.\(^17,18\) In another study, children who were EBV seropositive at 24 months were less likely to be IgE-sensitized at this age compared to EBV-seronegative children and this association was enhanced among children co-infected with CMV.\(^19\) Another analysis by the same group showed that children infected with EBV before 2 years were less likely to be IgE-sensitized at age 2 and 5 years while those infected after 2 years were more likely to be IgE-sensitized at 5 years.\(^20\)

There was no association between CMV, EBV or VZV infection at age 12 months and eczema, asthma, hay fever, total serum IgE levels or allergic sensitization at age 7 in a German study.\(^21\) In a UK case-control study, there was no association between EBV or VZV infection and eczema in 1- to 4-year-olds.\(^22\) Other studies have examined the association between seropositivity to CMV, EBV, VZV and other infections and risk of atopy or eczema, hay fever, or asthma, but the combined evidence is inconclusive.\(^23-25\) In some, the findings were limited by a lack of statistical power, but in most, infection status was measured at only one time point, often at age 4 or older, so it was not possible to pinpoint age at infection more precisely. As herpesvirus infections are common, it is unlikely that infection persists associated with risk of disease, but alteration in risk could result from infection at a critical period in immune development. Measuring infection status at more than one age in the first years of life is therefore important. In the Born in Bradford Allergy and Infection Study, children were tested for CMV-, EBV- and VZV-IgG at 12 and 24 months. We have previously reported earlier infection in Pakistani compared to white British children.\(^26\) The aim of this analysis is to investigate whether earlier CMV and/or EBV infection protect against the development of atopy.

## 2 | METHODS

The Allergy and Infection Study (ALL IN) is a sub-study of the Born in Bradford birth cohort (BiB), described elsewhere.\(^27\) Children were eligible to participate if they were enrolled in BiB with a maternal baseline questionnaire available and were born on or after 1 March 2008. Parents were invited to participate in ALL IN just before the child’s first birthday. If they agreed, a home or clinic visit was arranged and informed consent was obtained. A blood sample was taken, and a questionnaire was completed at 12 months and again at 24 months of age. Serum aliquots were stored at −80°C. The questionnaires included detailed information on breastfeeding and childcare, and the standard International Study of Asthma and Allergies in Childhood (ISAAC) questions on potential risk factors for atopy (pets, damp, mould, fuel for cooking and heating, type of windows in the child’s bedroom, type of flooring, type of pillow and bedding for the child).\(^28\)

Of the 2559 children enrolled in ALL IN, serum samples were tested for CMV-IgG, EBV-IgG and VZV-IgG for 1000 children to establish age at infection; infected by 12 months; infected between 12 and 24 months; or uninfected at 24 months.\(^26\) Samples with concentration values of ≥6.0 AU/mL were considered as positive for CMV-IgG, and VCA IgG concentrations of ≥20 U/mL were considered as positive for EBV-IgG. For VZV, samples containing 160 mIU/mL were considered positive, those between 140 and 160 were equivocal and those less than 140 mIU/mL were deemed negative.

When the children were 4 years old, the parents were re-contacted and invited for a visit including a questionnaire and skin prick test (SPT), as part of the MeDALL (Mechanisms of the Development of Allergy) study.\(^29,30\) The SPT was performed according to a standard protocol using the following allergens: cat hair, dog hair, grass mix, house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae plus a positive control (histamine 1%) and a negative saline control (Allergopharma kits supplied by Diagenics Ltd). The mean wheal diameter was recorded for each allergen (and the diameter of any wheal from the negative control subtracted). A wheal diameter of ≥3 mm was considered a positive reaction. Children with a positive reaction to at least one allergen were defined as atopic.

The community research staff were trained in SPT, with quality control procedures to assess intra-observer variability; all staff had to perform two monthly quality checks and achieve a coefficient of variation of less than 20 in their SPT series.
Parents were given the results of their child’s SPT with written guidance on allergen avoidance for those with positive tests.

This study had ethical approval from the London School of Hygiene & Tropical Medicine ethics committee (refs: 5320 and 6249) and the Bradford Research Ethics committee (refs: 08/H1302/21 and 12/YH/0252).

2.1 | Statistical analysis

Data analysis was conducted using Stata version 14. Frequency distributions for key variables described the children and their mothers. Cross-tabulations showed associations between these variables and atopic status. Age at CMV, EBV and VZV infection were the key exposures of interest. The outcome for this analysis was measured at age 4 years only and in all children at the same age. Our data therefore provide an estimate of prevalence, not risk, of atopy, so it is appropriate to present prevalence odds ratios from logistic regression analysis. If univariable analysis demonstrated an association with atopy, the relevant variable was included as a confounder in the multiple logistic regression analysis. The findings for age at CMV infection were compared between the univariable and multiple logistic regression analyses, and no evidence of multicollinearity was found, so the multiple regression analysis was accepted as the final model. Birth order and duration of breastfeeding were included in the CMV model a priori as these are strongly associated with age at CMV infection and associated with atopy in other studies. Effect modification by sex and ethnic group was investigated.

Previous studies have indicated interaction between EBV and CMV infection on atopy/IgE sensitization, so we compared the proportion of children who were atopic for combinations of age at CMV/EBV/VZV infection.

The number and type of positive allergens per child were described and examined by ethnic group and sex.

3 | RESULTS

SPT was completed at the 4-year visit for 740 children with serological data. Of these, 135 (18%) were atopic (95% CI 16-21).

Table 1 shows the characteristics of the children and their mothers.

3.1 | Unadjusted analysis

Among the children who were CMV infected by 12 months and those who remained uninfected at 24 months, 17% were atopic (31/181 and 82/485, respectively). However, of the 74 children who were CMV infected between 12 and 24 months, 30% (22) were atopic. There were no differences in the proportion of children atopic by age at EBV infection or by age at VZV infection (18% or 19% in each group).

Boys were twice as likely to be atopic than girls, and Pakistani children were twice as likely to be atopic than White British children. Childcare attendance by age 24 months, reporting pets in the home and central heating at the 12-month visit, and smoking in pregnancy were associated with reduced risk of atopy. Low birthweight and damp reported at 12 months were associated with an increased risk of atopy (Table 1). There was not strong evidence of an association with pets and damp reported at the 24-month visit. There was no evidence of associations between atopy and mould in the home, type of windows in child’s bedroom, gas for cooking, gas fire, wood or coal fire with chimney, type of flooring or bedding (data not shown).

Only nine respondents reported making changes due to asthma/allergies (mainly changing to hard floors or new carpets, different bedding) at the 12-month questionnaire (three were atopic), and only 17 reported making changes at the 24-month questionnaire (five were atopic).

The associations of atopy with breastfeeding, childcare, pets and smoking in pregnancy may reflect differences in the prevalence of these factors between white British and Pakistani children; Pakistani women were more likely to breastfeed, less likely to use childcare and far less likely to smoke than white British women. Pakistani families were less likely to have pets than white British families.

The 740 children included here were generally similar to the total 1000 children with serological data, although there was a slightly higher proportion of Pakistani children.

3.2 | Adjusted analysis

There was some evidence of effect modification of the association between age at CMV infection and atopy by sex (LRT $\chi^2 = 4.80$, $P = 0.09$), adjusting for ethnic group, birth order, duration of breastfeeding, regular childcare attendance by 24 months, low birthweight, pets in the home (12 months), damp (12 months), smoking pregnancy and central heating (12 months). In boys, there was no association between CMV infection in the second year and odds of atopy (adjusted OR [aOR] 1.20, 95% CI 0.52-2.79) and weak evidence of a protective effect of infection before 12 months (aOR 0.57, 95% CI 0.31-1.04). In girls, there was a strong association of CMV infection with atopy (aOR 2.85, 95% CI 1.29-6.30). There was no evidence of effect modification by sex of the association between age at CMV, EBV or VZV infection and atopy.

The 740 children included here were generally similar to the total 1000 children with serological data, although there was a slightly higher proportion of Pakistani children.

3.2 | Adjusted analysis

There was some evidence of effect modification of the association between age at CMV, EBV and VZV infection and atopy by sex (LRT $\chi^2 = 4.80$, $P = 0.09$), adjusting for ethnic group, birth order, duration of breastfeeding, regular childcare attendance by 24 months, low birthweight, pets in the home (12 months), damp (12 months), smoking pregnancy and central heating (12 months). In boys, there was no association between CMV infection in the second year and odds of atopy (adjusted OR [aOR] 1.20, 95% CI 0.52-2.79) and weak evidence of a protective effect of infection before 12 months (aOR 0.57, 95% CI 0.31-1.04). In girls, there was a strong association of CMV infection in the second year with increased odds of atopy (aOR 4.38, 95% CI 1.87-10.29) and no association with infection in the first year (aOR 0.97, 95% CI 0.40-2.33; Table 2).

There was also evidence of effect modification by sex of the association between age at EBV infection and atopy (LRT $\chi^2 = 5.87$, $P = 0.05$) and age at VZV infection and atopy (LRT $\chi^2 = 8.52$, $P = 0.01$); the sex-specific estimates are presented in Table 2. Girls infected with VZV in the second year of life were at increased odds of atopy (aOR 2.85, 95% CI 1.29-6.30). There was no evidence of effect modification by ethnic group of the association between age at CMV, EBV or VZV infection and atopy.

Table 1 shows the adjusted estimates (from the model for age at CMV infection) for the other variables associated with atopy. Boys had three times the odds of atopy overall compared to girls. The increased risk of atopy among Pakistani compared to White British children attenuated in multivariable analysis. There was weak evidence that children of low birthweight, those breastfed for more than 12 months and
### TABLE 1  Characteristics of the 740 children and their mothers and associations with atopy at age 4 y

| Characteristic                                      | N (% ) | Number of children atopic (%) | Unadjusted OR, 95% CI, P | Adjusted OR, 95% CI, P |
|-----------------------------------------------------|--------|-------------------------------|--------------------------|------------------------|
| **Age at CMV infection**                            |        |                               |                          |                        |
| By 12 mo                                            | 181 (24%) | 31 (17)                       | 1.02 (0.65-1.60), 0.95   | See Table 2 for sex-specified estimates |
| 12-24 mo                                            | 74 (10%)  | 22 (30)                       | 2.08 (1.20-3.61), 0.009  |                        |
| Uninfected at 24 mo                                 | 485 (66%) | 82 (17)                       | 1.0                      |                        |
| **Age at EBV infection**                            |        |                               |                          |                        |
| By 12 mo                                            | 112 (15%) | 21 (19)                       | 1.07 (0.63-1.83), 0.80   | See Table 2 for sex-specified estimates |
| 12-24 mo                                            | 193 (26%) | 37 (19)                       | 1.10 (0.71-1.70), 0.66   |                        |
| Uninfected at 24 mo                                 | 435 (59%) | 77 (18)                       | 1.0                      |                        |
| **Age at VZV infection**                            |        |                               |                          |                        |
| By 12 mo                                            | 66 (9%)  | 12 (18)                       | 1.00 (0.52-1.95), 0.99   | See Table 2 for sex-specified estimates |
| 12-24 mo                                            | 128 (17%) | 24 (19)                       | 1.04 (0.64-1.71), 0.87   |                        |
| Uninfected at 24 mo                                 | 546 (74%) | 99 (18)                       | 1.0                      |                        |
| **Mother's ethnic group**                           |        |                               |                          |                        |
| White British                                       | 258 (35%) | 28 (11%)                      | 1.0                      | 1.0                    |
| Pakistani                                           | 386 (52%) | 89 (23%)                      | 2.46 (1.56-3.89), <0.001 | 1.78 (0.96-3.31), 0.07 |
| Other                                               | 96 (13%)  | 18 (19%)                      | 1.90 (0.99-3.61), 0.05   | 1.36 (0.65-2.85), 0.41 |
| **Sex**                                             |        |                               |                          |                        |
| Female                                              | 343 (46%) | 40 (12%)                      | 1.0                      | 1.0                    |
| Male                                                | 397 (54%) | 95 (24%)                      | 2.38 (1.59-3.56), <0.001 | 3.28 (1.87-5.76), <0.001 |
| **Birth order**                                     |        |                               |                          |                        |
| 1                                                   | 257 (35%) | 47 (18%)                      | 1.0                      | 1.0                    |
| 2                                                   | 208 (28%) | 31 (15%)                      | 0.78 (0.48-1.28), 0.33   | 0.73 (0.43-1.25), 0.25 |
| 3+                                                  | 275 (37%) | 57 (21%)                      | 1.17 (0.76-1.80), 0.48   | 0.86 (0.53-1.41), 0.56 |
| **Duration of breastfeeding**                        |        |                               |                          |                        |
| Never                                               | 126 (17%) | 20 (16%)                      | 1.0                      | 1.0                    |
| 0-12 mo                                             | 510 (69%) | 88 (17%)                      | 1.11 (0.65-1.88), 0.71   | 1.19 (0.66-2.13), 0.56 |
| >12 mo                                              | 102 (14%) | 26 (25%)                      | 1.81 (0.94-3.48), 0.07   | 1.93 (0.93-4.00), 0.08 |
| **Missing**                                         |        | 2                              |                          |                        |
| **Regular childcare attendance by 24 mo**            |        |                               |                          |                        |
| Ever                                                | 293 (40%) | 41 (14%)                      | 0.61 (0.41-0.91), 0.02   | 0.79 (0.49-1.29), 0.35 |
| Never                                               | 447     | 94 (21%)                      | 1.0                      | 1.0                    |
| **Low birthweight (<2500 g)**                       |        |                               |                          |                        |
| Yes                                                 | 63 (9%)  | 16 (25%)                      | 1.60 (0.88-2.91), 0.13   | 1.90 (1.00-3.62), 0.05 |
| No                                                  | 677     | 119 (18%)                     | 1.0                      | 1.0                    |
| **Pets in the home (at 12 mo)**                     |        |                               |                          |                        |
| Yes                                                 | 185 (25%) | 25 (14%)                      | 0.63 (0.39-1.01), 0.06   | 0.87 (0.50-1.49), 0.60 |
| No                                                  | 550     | 109 (20%)                     | 1.0                      | 1.0                    |
| **Missing**                                         |        | 5                              |                          |                        |
| **Damp (damp spots on walls or ceilings) at 12 mo** |        |                               |                          |                        |
| Yes                                                 | 168 (23%) | 42 (25%)                      | 1.70 (1.12-2.57), 0.01   | 1.68 (1.08-2.62), 0.02 |
| No                                                  | 567     | 93 (16%)                      | 1.0                      | 1.0                    |
| **Missing**                                         |        | 5                              |                          |                        |

(Continues)
children living in homes without central heating had around twice the odds of atopy. There was good evidence that children living in damp homes were more likely to be atopic.

3.3 Infection with more than one virus in the second year is associated with greater risk of atopy

Of the total 740 children, 23 were infected with CMV and EBV between 12 and 24 months; 8 of 23 (35%) were atopic. Among 33 children who were CMV and EBV infected by 12 months, 6 (18%) were atopic. Similarly, among 121 children who were CMV and EBV infected by 24 months, 25 (21%) were atopic. Of 20 children who were CMV and VZV infected between 12 and 24 months, 9 (45%) were atopic, and of five children who were infected with all three viruses between 12 and 24 months, 4 (80%) were atopic. The final model for age at CMV infection, stratified by EBV infection status at 24 months, gave similar estimates to the overall results (data not shown).
3.4 | Ethnic group differences in atopy

Among 386 Pakistani mothers, 250 were born outside, and 136 were born in, the UK. Sixty-four (26%) children of those born outside the UK were atopic compared to 25 (18%) children of women born in the UK ($\chi^2 = 2.59, P = 0.11$). Twenty-seven (11%) children of White British women born in the UK were atopic. Only two of the White British women were born abroad (and one child was atopic).

3.5 | Which allergens were positive?

There were five allergens in the panel. Most of the 135 atopic children were positive for one ($n = 56$) or two ($n = 52$) allergens (Table 3). Positive reactions to house dust mites (HDM) were most common, followed by grass mix with positive cat and dog results the least common. The number of positive allergens per child did not vary substantially by ethnic group or sex.

Pakistani children were more likely to have a positive test for HDM than White British children. Among 56 children who reacted to one allergen, 33 (83%) of 40 Pakistani children were positive to HDM compared to 5 (50%) of the 10 White British children ($\chi^2 = 4.63, Fisher's exact $P = 0.05$). All except two children (1 WB, 1 Pakistani) with two positive reactions and all except one child (WB) with three positive reactions were positive for at least one HDM.

Among 56 children who reacted to one allergen, a higher proportion of boys were positive to HDM than girls but there was no evidence of a true difference ($\chi^2 = 1.38, P = 0.24$). Among 52 children who reacted to two allergens, all except one boy and one girl were positive for one or both HDM, and among 21 children with three positive reactions, all except one boy were positive for one or both HDM.
Our main finding is that, among the girls, CMV infection in the second year of life is associated with a fourfold increased odds of atopy compared to acquiring it in the first year or remaining uninfected at 2 years. Among the boys, there was no association between infection at 12-24 months and atopy, but weak evidence of a protective effect of CMV infection in the first year of life on odds of atopy. Although age at EBV infection and age at VZV infection were not associated with risk of atopy in unadjusted analyses, there was good evidence of effect modification by sex. Stratified, adjusted estimates revealed an increased odds of atopy among girls infected with VZV in the second year of life compared to those still uninfected at 2 years.

Traditionally, until 50-70 years ago in the UK and in low-income countries today, most children became infected with CMV by the age of 12 months. One explanation for our findings is that “delayed” infection, coinciding with immune development in the second year of life, may disrupt the balance of immune responses, leading to atopy. A second potential explanation is that CMV infection acquired when maternal antibody titres are declining might present a lower initial viral load to the immune system than found with perinatal infection from breast milk or infection later in life. Further studies are needed on this and should be linked to our observation of increased atopy in those of low birthweight who would have reduced placental passage of IgG.

The consistent direction of the sex-specific estimates for CMV, EBV and VZV, with increased odds of atopy among girls infected in the second year with CMV and with VZV, supports the biological plausibility of a sex-specific mechanism in the development of atopy. The “critical window” seems to be the second year of life when also considering combinations of CMV, EBV and VZV infections; the highest proportion of atopic children were among those infected in the second year of life with one or more viruses. Some evidence of a protective effect of CMV infection in the first year of life, at least in boys, fits with the traditional age at infection and corresponding low prevalence of atopy and demonstrates the importance of differentiating between infection in the first and second years.

Our results highlight potential sex-specific effects of age at CMV infection on risk of atopy. Overall, boys had a greater risk of atopy than girls, as reported in other studies, but differences in risk of atopy by age at CMV infection were only observed for girls. So why is “delayed” CMV infection associated with atopy in girls but not in boys?

There are other examples of sex differences in response or susceptibility to infections early in life and neonatal vitamin A supplementation (NVAS) was associated with increased atopy in girls but not boys in long-term follow-up of children enrolled in a previous randomized controlled trial in Guinea-Bissau. As in our study, females were less likely to be atopic than males overall, but those receiving NVAS were at increased risk of atopy (adjusted RR = 1.78, 95% CI 1.17-2.71) and wheeze during childhood (adjusted RR = 1.78, 95% CI 1.02-3.09) compared to those receiving placebo. Possible mechanisms to explain these associations are that retinoic acids from vitamin A can lead to an enhanced Th2 response and a reduced Th1 response. High oestrogen levels can also promote a Th2 response, and girls experience surges in oestrogen levels in early infancy as well as in puberty. A further study by the group demonstrates that NVAS is associated with differences in response to BCG vaccination by sex and increased pro- to anti-inflammatory cytokine ratios in females but decreased ratios in males, at 4-6 months of age.

In the Generation R cohort (population-based cohort from foetal life onwards, in Rotterdam, the Netherlands), no interaction of sex and CMV infection was observed in relation to immune phenotypes but the children were tested at age 6 years, so differences by age at infection could not be investigated. In exploratory studies of the same cohort, an impact of female sex and CMV infection on immune cell dynamics in early childhood has been demonstrated.

The combined evidence indicates that the sex-specific associations we have observed may provide clues about the mechanisms involved in the development of atopy. There is evidence that CMV influences anti-inflammatory mediators (viral and host IL-10). CMV infection may therefore influence the Th1/Th2 balance particularly in the second year of life, and this, combined with hormonal effects in girls, could increase the risk of atopy. It is also possible that the reverse is true: early immune changes which lead to atopy may be associated with delayed CMV infection.

The group of children who were CMV infected in the second year is relatively small, only 10% of the total, and the majority of children in this cohort remained uninfected at age 2 years. Their risk of atopy was similar to those infected in the first year, and we do not know the age distribution of subsequent CMV infection in this group. However, we assume that CMV infection during early

**TABLE 3** Number of positive reactions by allergen

| Allergen     | Number of positive reactions | Total |
|--------------|------------------------------|-------|
|              | 1 (2%) 2 (4%) 13 (23%) 27 (48%) 13 (23%) |       |
| Cat          | 5 (5%) 6 (6%) 6 (6%) 48 (46%) 45 (43%) |       |
| Dog          | 5 (8%) 2 (3%) 16 (25%) 20 (32%) 20 (32%) |       |
| Grass mix    | 3 (12%) 3 (13%) 5 (25%) 6 (25%)        |       |
| Mite 1 (D. Pter) | 48 (46%) 48 (46%) 20 (32%) 20 (32%) |       |
| Mite 2 (D. Farin) | 56 (52 children) 104 (52 children) 63 (21 children) 24 (6 children) | 135 |

**DISCUSSION**
immune development, that is the first 2-3 years, influences risk of atopy at age 4 years, and later infection has less impact.

We did not observe any differences in risk of atopy by age at EBV infection, in contrast to the Swedish studies, although there was evidence of effect modification by sex. EBV infection tends to be acquired later than CMV; in this cohort, most of the CMV infections occurred in the first year, usually through contact with the mother, whereas most EBV infections occurred in the second year via contact with siblings and other children. Delayed infection for EBV is therefore around age 3 or 4 years and older. A comparison of children infected by age 2 years (the “traditional” age at infection) with those infected between 2 and 4 years (delayed infection) would demonstrate any effect on risk of atopy, and we did not carry out serological testing at age 4 years. However, an effect on atopy risk would only be expected if the delayed infection coincided with a critical period of immune development. Similarly, VZV infection is usually acquired around age 3 or 4 years through contact with other children and we show that infection during the second year of life, a likely critical period of immune development, is associated with increased odds of atopy.

The 18% prevalence of atopy in our study is generally consistent with results from other European birth cohorts and UK studies. Some of these measured allergen-specific IgE (sIgE) in serum rather than SPT, and the children included ranged from age 2 to 7 years with all primary school-aged children included in one study.

The higher odds of atopy among Pakistani children, although attenuated in multivariable analysis, especially when including childcare in the model, is of interest, and there was some evidence of a higher risk of atopy in children of women born abroad and recently migrated to the UK. In the US NHANES study, allergic sensitization was associated with ethnicity and among those aged 1-5 years was less prevalent in non-Hispanic white children than other ethnic groups. The number of positive allergens per child did not vary by ethnicity, but there was weak evidence that Pakistani children were more likely to have a positive test to HDM than White British children. Higher levels of HDM and sensitization to HDM have been associated with damp in the home. In our study, a higher proportion of Pakistani children had damp in the home at 12 months than White British children, which might partly explain the higher odds of atopy in Pakistani children.

The key strength of our study is having infection status at both 12 and 24 months. To our knowledge, this is the first study to measure CMV- and EBV-IgG at 12 and 24 months in relation to atopic status. The benefits of the cohort design included risk factor data collected at 12 and 24 months, and at 4 years, whereas cross-sectional studies may not capture earlier exposures accurately either due to recall bias or if there are changes between age 1 and 4 years, which may have been made in response to allergic symptoms. There were few reported changes due to asthma or allergies at the 12- and 24-month questionnaire.

SPT is widely used and accepted as a valid tool to define atopy. Several members of the team carried out the tests, and there may have been variations in technique between them, despite training and quality control checks. However, any measurement error and subsequent misclassification of atopic status would have been non-differential, as the research team were unaware of the infection status of the children. Some studies use sIgE to define atopic status, instead of, or in addition to, SPT. There is generally good correlation between sIgE and SPT (>70% concordance), at least in high-income country settings.

Not all children with a positive SPT will develop clinical symptoms of eczema, hay fever or allergic asthma. Some non-atopic children may develop different types of asthma caused by non-atopic mechanisms. Further work will investigate whether the higher odds of atopy among girls infected with CMV in the second year translates to an increased risk of eczema, hay fever, wheeze or asthma among these children.

In conclusion, our results highlight potential sex-specific effects of age at CMV infection and age at VZV infection on risk of atopy, which may provide insight into the mechanisms involved in the development of atopy.

ACKNOWLEDGMENTS

Born in Bradford is only possible because of the enthusiasm and commitment of the Children and Parents in BiB. We are grateful to all the participants, health professionals and researchers who have made Born in Bradford happen. We would like to thank Andy Hall (previously at LSHTM, now retired) for his work on ALL IN, Pauline Raynor (former BiB Programme Manager) for her work in helping set up ALL IN, the BiB Community Research Administrators who carried out the ALL IN and MedALL visits, and Neil Pearce and Martin Goodier (LSHTM) for helpful comments on the manuscript.

CONFLICT OF INTEREST

The authors have no conflicts of interest in relation to this work.

AUTHORS’ CONTRIBUTIONS

LP conceived and designed the study, analysed and interpreted the data and drafted and revised the manuscript. DW co-ordinated data collection, interpreted the data and revised the manuscript. PG designed the study, interpreted the data and revised the manuscript. JW designed the study, interpreted the data and revised the manuscript. All authors have given final approval of the version to be published.

ORCID

Lucy Pembrey https://orcid.org/0000-0002-0455-7469

REFERENCES

1. Strachan DP. Family size, infection and atopy: the first decade of the "hygiene hypothesis". Thorax. 2000;55(Suppl 1):S2-S10.
3. McKeever TM, Lewis SA, Smith C, et al. Siblings, multiple births, and the incidence of allergic disease: a birth cohort study using the West Midlands general practice research database. Thorax. 2001;56(10):758-762.

4. Burbank AJ, Sood AK, Kesic MJ, Peden DB, Hernandez ML. Environmental determinants of allergy and asthma in early life. J Allergy Clin Immunol. 2017;140(1):1-12.

5. Forastiere F, Agabiti N, Corbo GM, et al. Socioeconomic status, number of siblings, and respiratory infections in early life as determinants of atopy in children. Epidemiology. 1997;8(5):566-570.

6. Bodner C, Godden D, Seaton A. Family size, childhood infections and atopic diseases. The Aberdeen WHEASE Group. Thorax. 1998;53(1):28-32.

7. von Mutius E, Illi S, Hirschl T, Leupold W, Keil U, Weiland SK. Frequency of infections and risk of asthma, atopy and airway hyperresponsiveness in children. Eur Respir J. 1999;14(1):4-11.

8. La Rosa C, Diamond DJ. The immune response to human CMV. Future Virol. 2012;7(3):279-293.

9. Hatton OL, Harris-Arnold A, Schaffert S, Krams SM, Martinez OM. The interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and disease. Immunol Res. 2014;58(2-3):268-276.

10. Miles D, van der Sande M, Jeffries D, et al. Maintenance of large subpopulations of differentiated CD8 T-cells two years after cytomegalovirus infection in Gambian infants. PLoS ONE. 2008;3(8):e2905.

11. Guma M, Budt M, Saez A, et al. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood. 2006;107(9):3624-3631.

12. Lee J, Zhang T, Hwang I, et al. Epigenetic modification and infectious burden on the prevalence of atopy and respiratory allergy in children. Pediatr Pulm Dis. 2017;17(1):220.

13. Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE. The immune response to human CMV. Future Virol. 2011;5(9):835-870.

14. Pawelec G, Derhovanessian E. Role of CMV in immune senescence. Virus Res. 2011;157(2):175-179.

15. Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol (Paris). 2015;172(1):3-13.

16. Cohen JI, Fauci AS, Varunis H, Nabel GJ, Varmus H, Nabel GJ. Epstein-Barr virus: an important vaccine target for cancer prevention. Sci Trans Med. 2011;3(107):107fl107.

17. Sidorchuk A, Lagarde F, Pershagen G, Wickman M, Linde A. Epstein-Barr virus infection is not associated with development of allergy in children. Pediatr Infect Dis J. 2003;22(7):642-647.

18. Sidorchuk A, Wickman M, Pershagen G, Lagarde F, Linde A. Cytomegalovirus infection and development of allergic diseases in early childhood: interaction with EBV infection? J Allergy Clin Immunol. 2004;114(6):1434-1440.

19. Nilsson C, Linde A, Montgomery SM, et al. Does early EBV infection protect against IgE sensitization? J Allergy Clin Immunol. 2005;116(2):438-444.

20. Saghafian-Hedengren S, Sverremark-Ekstrom E, Linde A, Lilja G, Nilsson C. Early-life EBV infection protects against persistent IgE sensitization. J Allergy Clin Immunol. 2010;125(2):433-438.

21. Laske N, Volk H-D, Liebenthal C, et al. Infantile natural immunization to herpes group viruses is unrelated to the development of asthma and atopic phenotypes in childhood. J Allergy Clin Immunol. 2002;110(5):811-813.

22. Gibbs S, Surridge H, Adamson R, Cohen B, Bentham G, Reading R. Atopic dermatitis and the hygiene hypothesis: a case-control study. Int J Epidemiol. 2004;33(1):199-207.

23. Alcantara-Neves NM, Veiga RV, Dattoli VC, et al. The effect of single and multiple infections on atopy and wheezing in children. J Allergy Clin Immunol. 2012;129(2):359-367, 367 e351-353.

24. Janson C, Asbjornsodttr H, Birgisodottir A, et al. The effect of infectious burden on the prevalence of atopy and respiratory allergies in Iceland, Estonia, and Sweden. J Allergy Clin Immunol. 2007;120(3):673-679.

25. Veiga RV, Cunha SS, Dattoli V, et al. Chronic virus infections suppress atopy but not asthma in a set of children from a large Latin American city: a cross-section study. BMC Pulm Med. 2011;11:24.

26. Pembrey L, Waiblinger D, Griffiths P, Patel M, Azad R, Wright J. Cytomegalovirus, Epstein-Barr virus and varicella zoster virus infection in the first two years of life: a cohort study in Bradford, UK. BMC Infec Dis. 2017;17(1):220.

27. Wright J, Small N, Raynor P, et al. Cohort profile: the Born in Bradford multi-ethnic family cohort study. Int J Epidemiol. 2013;42(4):978-991.

28. Weiland SK, Bjorksten B, Bruneckef B, Cookson WO, von Mutius E, Strachan DP. Phase II of the International Study of Asthma and Allergies in Childhood (ISAAC II): rationale and methods. Eur Respir J. 2004;24(3):406-412.

29. Bousquet J, Anto J, Auffray C, et al. Mechanisms of the Development of Allergies: an integrated approach from phenotypes to systems medicine. Allergy. 2011;66(5):596-604.

30. Hohmann C, Pinart M, Tischer C, et al. The development of the MeDALL Core Questionnaires for a harmonized follow-up assessment of eleven European birth cohorts on asthma and allergies. Int Arch Allergy Immunol. 2014;163(3):215-224.

31. Staia Statistical Software: Release 14 [computer program]. College Station, TX: StataCorp LP; 2015.

32. Upchurch S, Harris JM, Cullinan P. Temporal changes in UK birth order and the prevalence of atopy. Allergy. 2010;65(8):1039-1041.

33. Oddy WH, Sherriff JL. Breastfeeding, body mass index, asthma and atopy in children. Asia Pac J Public Health. 2003;15(Suppl):S51-S57.

34. Mihrshahi S, Ampon R, Webb K, et al. The association between infant feeding practices and subsequent atopy among children with a family history of asthma. Clin Exp Allergy. 2007;37(5):671-679.

35. Jansen M, van den Heuvel D, Jaddoe V, Moll HA, van Zelm MC. No interactive effects of sex and persistent cytomegalovirus on immune phenotypes in young children: the generation R study. J Infect Dis. 2017;215(6):883-888.

36. Holder B, Miles D, Kaye S, et al. Epstein-Barr virus but not cytomegalovirus is associated with reduced vaccine antibody responses in Gambian infants. PLoS ONE. 2010;5(11):e14013.

37. Grose C, Johanson DC. Transmission of Cytomegalovirus, Epstein-Barr Virus, and Herpes Simplex Virus Infections: From the Lucy Australopithecus Epoch to Modern-Day Netherlands. J Pediatr. 2016;170:9-10.

38. Ukert S, Akan G, Evans M, et al. Sex-related differences in immune development and the expression of atopy in early childhood. J Allergy Clin Immunol. 2006;118(6):1375-1381.

39. Salo PM, Arbes SJ, Jaramillo R, et al. Prevalence of allergic sensitization in the United States: results from the National Health and Nutrition Examination Survey (NHANES) 2005–2006. J Allergy Clin Immunol. 2014;134(2):350-359.

40. Thorne C, Newell ML. European Collaborative Study. Are girls more at risk of intrauterine-acquired HIV infection than boys? AIDS. 2004;18(2):344-347.

41. European Paediatric Hepatitis C Virus Network. A significant sex—but not elective cesarean section—effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis. 2005;192(11):1872-1879.

42. Aage S, Kiraly N, Da Costa K, et al. Neonatal vitamin A supplementation associated with increased atopy in girls. Allergy. 2015;70(8):985-994.
43. Jensen KJ, Sondergaard MJ, Andersen A, et al. Long-term sex-differential effects of neonatal vitamin A supplementation on in vitro cytokine responses. Br J Nutr. 2017;118(11):942-948.
44. van den Heuvel D, Jansen M, Nasserinejad K, et al. Effects of non-genetic factors on immune cell dynamics in early childhood. The Generation R Study. J Allergy Clin Immunol. 2017;139(6):1923-1934 e1917.
45. Avdic S, McSharry BP, Steain M, et al. Human Cytomegalovirus-Encoded Human Interleukin-10 (IL-10) Homolog Amplifies Its Immunomodulatory Potential by Upregulating Human IL-10 in Monocytes. J Virol. 2016;90(8):3819-3827.
46. Gruzieva O, Gehring U, Aalberse R, et al. Meta-analysis of air pollution exposure association with allergic sensitization in European birth cohorts. J Allergy Clin Immunol. 2014;133(3):767-776 e767.
47. Perkin MR, Strachan DP. Which aspects of the farming lifestyle explain the inverse association with childhood allergy? J Allergy Clin Immunol. 2006;117(6):1374-1381.
48. Collin SM, Granell R, Westgarth C, et al. Pet ownership is associated with increased risk of non-atopic asthma and reduced risk of atopy in childhood: findings from a UK birth cohort. Clin Exp Allergy. 2015;45(1):200-210.
49. Weinmayr G, Gehring U, Genuweit J, et al. Dampness and moulds in relation to respiratory and allergic symptoms in children: results from Phase Two of the International Study of Asthma and Allergies in Childhood (ISAAC Phase Two). Clin Exp Allergy. 2013;43(7):762-774.
50. Knight V, Wolf ML, Trikha A, Curran-Evenet D, Hiserote M, Harbeck RJ. A comparison of specific IgE and skin prick test results to common environmental allergens using the HYTEC 288. J Immunol Methods. 2018;462:9-12.
51. Ewan PW, Coote D. Evaluation of a capsulated hydrophilic carrier polymer (the ImmunoCAP) for measurement of specific IgE antibodies. Allergy. 1990;45(1):22-29.

How to cite this article: Pembrey L, Waiblinger D, Griffiths P, Wright J. Age at cytomegalovirus, Epstein Barr virus and varicella zoster virus infection and risk of atopy: The Born in Bradford cohort, UK. Pediatr Allergy Immunol. 2019;30:604-613. https://doi.org/10.1111/pai.13093